PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33674983-4	2021	Rivaroxaban is a direct inhibitor of activated factor Xa and has the advantage of predictable pharmacodynamics and pharmacokinetics, no coagulation monitoring, and few drug interactions.	rivaroxaban	0-11	coagulation factor X	Homo sapiens	47-56	
32023227-1	2020	Rivaroxaban is a direct oral anti-factor Xa anticoagulant.	rivaroxaban	0-11	coagulation factor X	Homo sapiens	34-43	
31746285-4	2021	Then, in 2018, andexanet alpha, a recombinant factor Xa, was approved for the reversal of apixaban and rivaroxaban in patients with life-threatening or uncontrolled bleeding.	rivaroxaban	103-114	coagulation factor X	Homo sapiens	46-55	
31793049-2	2020	Rivaroxaban, a direct factor Xa inhibitor, has demonstrated good effects in LV.1,3,4 Compared to other treatments such as classic anticoagulants or intravenous immunoglobulin, rivaroxaban is way more convenient since it does not require injection, international normalized ratio monitoring or hospitalization.	rivaroxaban	0-11	coagulation factor X	Homo sapiens	22-31	
31793049-2	2020	Rivaroxaban, a direct factor Xa inhibitor, has demonstrated good effects in LV.1,3,4 Compared to other treatments such as classic anticoagulants or intravenous immunoglobulin, rivaroxaban is way more convenient since it does not require injection, international normalized ratio monitoring or hospitalization.	rivaroxaban	176-187	coagulation factor X	Homo sapiens	22-31	
31839722-7	2020	Low molecular weight heparin anti-FXa activity cut-off values of 0.05 IU/mL and 0.1 IU/mL are suitable for excluding the presence of clinically relevant concentrations (< 30 ng/mL) of rivaroxaban and apixaban, respectively.	rivaroxaban	187-198	coagulation factor X	Homo sapiens	34-37	
31839722-9	2020	Conclusion: Low molecular weight heparin anti-FXa assay can be used in emergency clinical conditions for ruling out the presence of clinically relevant concentrations of rivaroxaban and apixaban.	rivaroxaban	170-181	coagulation factor X	Homo sapiens	46-49	
31877292-11	2020	When used in combination, rivaroxaban and dabigatran are more effective than either agent alone suggesting that concomitant inhibition of factor Xa and thrombin is better than inhibition of either clotting enzyme alone.	rivaroxaban	26-37	coagulation factor X	Homo sapiens	138-147	
31831187-6	2020	Andexanet alfa is a modified FXa molecule approved in the United States to reverse the anticoagulant effects of FXa inhibitors (rivaroxaban and apixaban) in patients with life-threatening or uncontrolled bleeding.	rivaroxaban	128-139	coagulation factor X	Homo sapiens	29-32	
31831187-6	2020	Andexanet alfa is a modified FXa molecule approved in the United States to reverse the anticoagulant effects of FXa inhibitors (rivaroxaban and apixaban) in patients with life-threatening or uncontrolled bleeding.	rivaroxaban	128-139	coagulation factor X	Homo sapiens	112-115	
31731710-1	2019	BACKGROUND: The direct oral anticoagulant rivaroxaban inhibiting specifically activated factor X (FXa) causes delayed thrombin generation (TG) as measured by calibrated automated thrombography (CAT).	rivaroxaban	42-53	coagulation factor X	Homo sapiens	98-101	
31808849-2	2019	He is anticoagulated with rivaroxaban (a direct oral factor Xa inhibitor [FXaI]) and received his last dose about 4 hours before presentation.	rivaroxaban	26-37	coagulation factor X	Homo sapiens	53-62	
31552542-1	2019	Direct oral anticoagulants (DOACs) include dabigatran, which inhibits thrombin, and apixaban, edoxaban, and rivaroxaban, which inhibit factor Xa.	rivaroxaban	108-119	coagulation factor X	Homo sapiens	135-144	
31768290-2	2019	Case Description: A 66-year-old female presented with a Brown-Sequard syndrome attributed to a cervical epidural hematoma secondary to the utilization of rivaroxaban, one of the factor Xa inhibitors.	rivaroxaban	154-165	coagulation factor X	Homo sapiens	178-187	
31649541-1	2019	Introduction: In patients treated with direct oral anti activated factor X (anti-FXa) anticoagulants such as apixaban and rivaroxaban, there are several emergency and non-emergency conditions in which anticoagulation activity should be measured.	rivaroxaban	122-133	coagulation factor X	Homo sapiens	81-84	
31649541-8	2019	There was a strong correlation between anti-FXa concentrations and INR in rivaroxaban treated patients (r = 0.899, p < 0.001).	rivaroxaban	74-85	coagulation factor X	Homo sapiens	44-47	
31649541-12	2019	Where anti-FXa assay is unavailable, our proposed formula may be considered as a screening test for rivaroxaban.	rivaroxaban	100-111	coagulation factor X	Homo sapiens	11-14	
31656515-1	2019	Rivaroxaban is one of the new anti-coagulants that inhibit Factor Xa and rarely cause rectus sheath hematoma and retroperitoneal haemorrhage which are uncommon, life-threatening complications.	rivaroxaban	0-11	coagulation factor X	Homo sapiens	59-68